NeuroSense Therapeutics Ltd.

<div class="infobox infobox-company">
<div class="infobox-header">NeuroSense Therapeutics Ltd.</div>
<div class="infobox-row"><strong>Headquarters:</strong> Netanya, Israel</div>
<div class="infobox-row"><strong>Founded:</strong> 2017</div>
<div class="infobox-row"><strong>Public:</strong> NASDAQ (NRSN)</div>
<div class="infobox-row"><strong>Market Cap:</strong> ~$30M USD (2026)</div>
<div class="infobox-row"><strong>Employees:</strong> ~20</div>
</div>

Overview

<div class="infobox infobox-company">
<div class="infobox-header">NeuroSense Therapeutics Ltd.</div>
<div class="infobox-row"><strong>Headquarters:</strong> Netanya, Israel</div>
<div class="infobox-row"><strong>Founded:</strong> 2017</div>
<div class="infobox-row"><strong>Public:</strong> NASDAQ (NRSN)</div>
<div class="infobox-row"><strong>Market Cap:</strong> ~$30M USD (2026)</div>
<div class="infobox-row"><strong>Employees:</strong> ~20</div>
</div>

Overview

NeuroSense Therapeutics is a clinical-stage biotechnology company developing novel treatments for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. Founded in 2017 and headquartered in Netanya, Israel, the company's lead product, Cognizance (formerly NC-1), is a novel combination therapy targeting multiple pathways involved in neurodegeneration["\^1"].

The company's approach addresses a critical unmet need in ALS: the failure of single-target approaches to meaningfully alter disease progression. By combining multiple neuroprotective agents, NeuroSense aims to achieve synergistic effects that may slow or halt disease progression["\^2"].

Company Background

Scientific Foundation

NeuroSense was founded based on research from Israeli academic institutions, particularly work on combination therapy approaches for neurodegenerative diseases. The company's scientific approach recognizes that ALS involves multiple pathological pathways, making multi-target therapy essential for meaningful clinical benefit.

Leadership

• Mr. Alon Ben-Noon (CEO) - Experienced biotech entrepreneur
• Dr. Ilan B. K. Dan (Chief Medical Officer) - Neurology expert with extensive clinical development experience

Pipeline / Products

Cognizance (NC-1) - Lead Program

Cognizance is NeuroSense's lead clinical candidate for ALS, a novel combination therapy consisting of multiple neuroprotective agents[\^3].

| Attribute | Details |
|-----------|---------|
| Composition | Combination of [NMDA receptor](/entities/nmda-receptor) modulator + antioxidant + anti-inflammatory |
| Mechanism | Multi-target neuroprotection |
| Indication | Amyotrophic Lateral Sclerosis (ALS) |
| Route | Oral |
| Development Phase | Phase 2b (PARADIGM trial) |
| Status | Active clinical development |

Mechanism of Action:
Cognizance works through multiple complementary mechanisms:

Clinical Development:

• Phase 1 (2019): Completed first-in-human study demonstrating safety
• Phase 2a PARADIGM (2022): Showed significant reduction in ALS progression rate compared to historical controls
• Phase 2b PARADIGM: Ongoing, expanding patient cohort

NC-2 - Alzheimer's Disease Program

NC-2 is a preclinical candidate for [Alzheimer's disease](/diseases/alzheimers-disease), leveraging the same multi-target approach[\^4].

| Attribute | Details |
|-----------|---------|
| Mechanism | Multi-target neuroprotection |
| Indication | Alzheimer's Disease |
| Development Phase | Preclinical |
| Status | Active research |

NC-3 - Parkinson's Disease Program

NC-3 is in discovery phase for [Parkinson's disease](/diseases/parkinsons-disease)[\^5].

| Attribute | Details |
|-----------|---------|
| Mechanism | Neuroprotection |
| Indication | Parkinson's Disease |
| Development Phase | Discovery |
| Status | Active research |

Technology Platform

Combination Therapy Approach

NeuroSense's platform is built on the principle that combination therapy is essential for neurodegenerative diseases:

• Multi-target intervention: Simultaneous targeting of multiple pathological pathways
• Synergistic effects: Combining agents with complementary mechanisms
• [BBB](/entities/blood-brain-barrier) penetration: Optimized for central nervous system delivery
• Safety profile: Using well-characterized agents with established safety

Advantages

Clinical Evidence

PARADIGM Phase 2a Results (2022)

The Phase 2a PARADIGM trial demonstrated[\^6]:

• Primary endpoint: Significant reduction in ALS Functional Rating Scale-Revised (ALSFRS-R) decline rate
• Secondary endpoints: Positive trends in respiratory function and quality of measures
• Safety: Good tolerability with no serious drug-related adverse events

Biomarker Studies

NeuroSense has also conducted biomarker studies showing:

• Reduction in [neurofilament light](/biomarkers/neurofilament-light-chain-nfl) chain (NfL) levels in treated patients
• Evidence of target engagement through relevant pharmacodynamic markers

Market Context

ALS Treatment Landscape

Amyotrophic lateral sclerosis remains a significant unmet medical need:

• Prevalence: ~30,000 patients in the US, 450,000 globally
• Current treatments: Only Riluzole and Edaravone (limited efficacy)
• Market opportunity: >$1B annually for effective disease-modifying therapy

Competitive Landscape

| Company | Drug | Mechanism | Stage |
|---------|------|-----------|-------|
| Amylyx Pharmaceuticals | Relyvrio | Combination (sodium phenylbutyrate/taurursodiol) | Approved |
| BrainStorm Cell Therapeutics | NurOwn | Cell therapy | Phase 3 |
| NeuroSense | Cognizance | Combination therapy | Phase 2b |
| Cytokinetics | Tirasemtiv | Fast skeletal muscle troponin activator | Phase 3 |

Funding & Financials

| Event | Year | Amount |
|-------|------|--------|
| IPO | 2021 | $25 million (NASDAQ) |
| Public Offering | 2022 | $8 million |
| ATM Offering | 2023 | $15 million |

Strategic Partnerships

NeuroSense has established collaborations with:

• Academic centers for clinical trial execution
• Contract research organizations (CROs) for preclinical studies

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References